sanjay pujari, md, fidsa institute of infectious diseases ... · sanjay pujari, md, fidsa institute...
TRANSCRIPT
![Page 1: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/1.jpg)
Opportunistic infections Sanjay Pujari, MD, FIDSA
Institute of Infectious Diseases, Pune, India
![Page 2: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/2.jpg)
Disclosures
• Advisory board, Speaker fees: Mylan, Hetero, Cipla ltd
![Page 3: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/3.jpg)
Outline
• Why OI’s still occur?
• Mycobacterial
• Fungal
• Viral
• Protozoal
![Page 4: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/4.jpg)
Decline in deaths esp d/t AIDS related illnesses
UNAIDS Data 2018
![Page 5: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/5.jpg)
However,
UNAIDS Data 2018
![Page 6: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/6.jpg)
Impact of cART on late presenters: LSOCA cohort
HIV Medicine 2018, 19, 411--419
![Page 7: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/7.jpg)
Impact of cART on late presenters: LSOCA cohort
HIV Medicine 2018, 19, 411--419
![Page 8: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/8.jpg)
Median CD4 counts at cART initiation
Clinical Infectious Diseases 2018;66(6):893–903
![Page 9: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/9.jpg)
Late initiation of cART
Clinical Infectious Diseases 2018;66(6):893–903
![Page 10: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/10.jpg)
Late presentation (CD4<350) to HIV care: Belgium
Sci Rep. 2018 Jun 5;8(1):8594
![Page 11: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/11.jpg)
Advanced disease (CD4<200) at presentation: Belgium
Sci Rep. 2018 Jun 5;8(1):8594
![Page 12: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/12.jpg)
The 90-90-90 status: Eastern Europe/Central Asia
UNAIDS Data 2018
![Page 13: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/13.jpg)
The 90-90-90 status: Western Europe/Central Europe/North America
UNAIDS Data 2018
![Page 14: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/14.jpg)
Outline
• Why OI’s still occur?
• Mycobacterial
• Fungal
• Viral
• Protozoal
![Page 15: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/15.jpg)
Prevalence of HIV in Individuals with TB
Global TB report 2017 http://www.who.int/tb/publications/global_report/en/
![Page 16: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/16.jpg)
TB incidence and deaths: 2000-2016
Global TB report 2017 http://www.who.int/tb/publications/global_report/en/
![Page 17: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/17.jpg)
Estimated deaths d/t HIV, TB: 2016
Global TB report 2017 http://www.who.int/tb/publications/global_report/en/
![Page 18: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/18.jpg)
TB incidence and CD4 counts: PLHIV not on cART
Peer J. 2017 Dec 14;5:e4165
![Page 19: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/19.jpg)
Clinical Scoring system for prioritizing investigation for TB: XPHACTOR score
PloS One 2017; 12:e0181519
![Page 20: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/20.jpg)
Clinical Scoring system for prioritizing investigation for TB: XPHACTOR score
PloS One 2017; 12:e0181519
![Page 21: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/21.jpg)
Screening with Xpert MTB and mortality: CHEPETSA trial
Clin Infect Dis. 2018 Jul 27 (epub ahead of print)
![Page 22: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/22.jpg)
Screening with Xpert MTB and mortality: CHEPETSA trial
Clin Infect Dis. 2018 Jul 27 (epub ahead of print)
![Page 23: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/23.jpg)
Urinary LAM + Xpert MTB screening for all inpatients: STAMP trial
Lancet 2018; 392: 292–301
![Page 24: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/24.jpg)
Urinary LAM + Xpert MTB screening for all inpatients: CD4<100 vs >100
Lancet 2018; 392: 292–301
![Page 25: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/25.jpg)
Urinary LAM + Xpert MTB screening for all inpatients: Hb < 8 vs > 8
Lancet 2018; 392: 292–301
![Page 26: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/26.jpg)
Ultra-Xpert: S-ve, culture +, PTB
Lancet Infect Dis 2018;18:76–84.
![Page 27: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/27.jpg)
HR drug concentrations and culture conversion
![Page 28: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/28.jpg)
DTG bid with RMP: INSPIRING study
10
20
30
40
50
60
70
80
90
100
DTG BID EFV
PVL<50
CROI 2018 abstr 28LB
![Page 29: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/29.jpg)
BIC with RMP
Mean BIC PK (% CV)
Cohort 1
BIC/FTC/TAF QD
(n = 26)
Cohort 2
BIC/FTC/TAF BID + RIF QD
(n = 26)
AUC0-24, ng*h/mL 115,200 (21) 45,600 (23)
Cmax, ng/mL 8530 (16) 4560 (19)
Ctrough, ng/mL 3070 (28) 608 (30)
CROI 2018, abstr 34
![Page 30: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/30.jpg)
TAF + RMP vs TDF- IC-TFV-DP: RIFT study
0
20000
40000
60000
80000
100000
120000
140000
TAF + RMP TDF
CROI 2018; abstr 28LB
![Page 31: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/31.jpg)
EFV400 with HR: study design
CROI 2018 abstr 457
![Page 32: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/32.jpg)
EFV concentrations with HR + EFV400
CROI 2018 abstr 457
![Page 33: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/33.jpg)
EFV + HR: Metabolizer status
CROI 2018 abstr 457
![Page 34: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/34.jpg)
Concurrent MDRTB and HIV treatment: SHOUT-MDRTB study
Clin Infect Dis 2018;66:1246–1253.
![Page 35: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/35.jpg)
Concurrent MDRTB and HIV treatment: SHOUT-MDRTB study
Clin Infect Dis 2018;66:1246–1253.
![Page 36: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/36.jpg)
No higher IRIS with RAL intensification: REALITY trial
CROI 2018, Abstr 23
![Page 37: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/37.jpg)
No higher IRIS with RAL intensification: REALITY trial
CROI 2018, Abstr 23
![Page 38: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/38.jpg)
Prophylactic steroids for paradoxical TB-IRIS: PRED-IRIS study
CROI 2017, abstr 81LB
![Page 39: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/39.jpg)
IPT and mortality benefit: TEMPARANO
Lancet Glob Health 2017; 5:e1080–e1089.
![Page 40: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/40.jpg)
IPT benefit according to QuantiFERON status
QunatiFERON-TB Gold +ve QuantiFERON-TB Gold -ve
Lancet Glob Health 2017; 5:e1080–e1089.
![Page 41: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/41.jpg)
3HP vs 9H for LTBI treatment: PREVENT TB trial
AIDS 2016, 30:1607–1615
![Page 42: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/42.jpg)
3HP vs 6H for LTBI treatment: completion rates PREVENT TB trial
0
10
20
30
40
50
60
70
80
90
100
3HP (DOT) 9H (SAT)
AIDS 2016, 30:1607–1615
P<0.001
![Page 43: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/43.jpg)
1HP vs 9H for preventing TB amongst PLHIV: BRIEF-TB/A5279
CROI 2018; Abstract 37LB
![Page 44: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/44.jpg)
Immediate IPT and pregnancy/birth outcomes: TB APPRISE study
CROI 2018; Abstract 142LB
![Page 45: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/45.jpg)
HIV/TB: Research ideas
• Evaluation of • Next generation urinary LAM assays • Diagnostic accuracy and Clinical outcomes of screening with Xpert-Ultra vs
Xpert in PTB and EPTB across different settings
• Efficacy and durability of shorter LTBI regimens (3HP, 1HP, 3R) in PLHIV with advanced disease initiating ART
• Operational research for TDM of anti-TB drugs in high HIV/TB areas
![Page 46: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/46.jpg)
Outline
• Why OI’s still occur?
• Mycobacterial
• Fungal
• Viral
• Protozoal
![Page 47: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/47.jpg)
sCrAG titers and CSF CrAG positivity
Clin Infect Dis. 2017 Nov 29;65(12):2126-2129
![Page 48: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/48.jpg)
Alternative regimens for CM induction treatment: ACTA trial
N Engl J Med. 2018 Mar 15;378(11):1004-1017
![Page 49: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/49.jpg)
ACTA: Alternative regimens for CM induction treatment
N Engl J Med. 2018 Mar 15;378(11):1004-1017
![Page 50: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/50.jpg)
Alternative regimens for CM induction treatment: ACTA trial
N Engl J Med. 2018 Mar 15;378(11):1004-1017
![Page 51: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/51.jpg)
ART timing in CM: All cause mortality
Cochrane Database Syst Rev. 2018 Jul 24;7:CD009012
![Page 52: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/52.jpg)
ART timing in CM: CM relapse
Cochrane Database Syst Rev. 2018 Jul 24;7:CD009012
![Page 53: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/53.jpg)
ART timing in CM: Cryptococcal IRIS
Cochrane Database Syst Rev. 2018 Jul 24;7:CD009012
![Page 54: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/54.jpg)
Histoplasma in Latin America
Lancet Infect Dis 2018; Aug 23
![Page 55: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/55.jpg)
Histo vs TB in Latin America
Lancet Infect Dis 2018; Aug 23
![Page 56: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/56.jpg)
Histo vs TB in Latin America
Lancet Infect Dis 2018; Aug 23
![Page 57: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/57.jpg)
HIV/fungal: Research ideas
• Management of PLHIV developing CM soon after initiating ART
• Evaluation and treatment of CM recurrence
• Flucoanazole for pre-emptive treatment of sCRAG+
• Role of echinocandins in severe PCP
![Page 58: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/58.jpg)
Outline
• Why do OI’s still occur?
• Mycobacterial
• Fungal
• Viral
• Protozoal
![Page 59: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/59.jpg)
HZ incidence in the cART era
Front Public Health. 2018 Mar 12;6:70. doi
![Page 60: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/60.jpg)
VZV live vaccine in PLHIV suppressed on ART and CD4>200/mm3
Clin Infect Dis. 2018 Mar 26 [Epub ahead of print]
![Page 61: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/61.jpg)
CMV viremia in advanced HIV improves with ART without anti-CMV treatment
CROI 2018, abstr 801
![Page 62: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/62.jpg)
PML incidence in France
Clin Infect Dis. 2018 Jul 2;67(2):275-282
![Page 63: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/63.jpg)
Risk of PML after cART initiation
Clin Infect Dis. 2018 Jul 2;67(2):275-282
![Page 64: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/64.jpg)
JCV DNA levels and PML
Clin Infect Dis. 2018 Jun 18;67(1):65-72
![Page 65: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/65.jpg)
HIV-L: Plasma EBV and survival
Clin Infect Dis. 2018 Jun 29
![Page 66: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/66.jpg)
HIV-L: Plasma EBV and survival
Clin Infect Dis. 2018 Jun 29
![Page 67: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/67.jpg)
qHPV vaccine efficacy in G/WLHIV
Clin Infect Dis. 2018 Jul 7. [Epub ahead of print]
![Page 68: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/68.jpg)
HIV/Viral: Research ideas
• Role of neurotropic viruses like HCV in PML onset
• Strategies to diagnose and manage PML IRIS
• Efficacy of HZ/su or ZV amongst elderly PLHIV
• Efficacy of nine-valent HPV vaccine in WHIV
• Use of EBV VL in prognostic scores for HIV- Lymphoma
![Page 69: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/69.jpg)
Outline
• Why do OI’s still occur?
• Mycobacterial
• Fungal
• Viral
• Protozoal
![Page 70: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/70.jpg)
T. gondii infection in PLHIV worldwide
Lancet HIV. 2017 Apr;4(4):e177-e188
![Page 71: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/71.jpg)
Cerebral toxoplasmosis: Treatment
HIV Med. 2017 Feb;18(2):115-124
![Page 72: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/72.jpg)
Summary
• OI’s: Going, Going, not gone
• Improving screening and diagnosis of TB: key to control TB in PLHIV
• Evidence for use of RAL/DTG with RMP: Encouraging and evolving
• Urgent access to flucytosine in LMICs needed
• Vaccine uptake needs to improve: reduce residual morbidity
![Page 73: Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases ... · Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India . Disclosures •Advisory board, Speaker fees:](https://reader030.vdocument.in/reader030/viewer/2022041102/5edcb93aad6a402d666782f6/html5/thumbnails/73.jpg)